DUBLIN--(BUSINESS WIRE)--Nov 20, 2019--

The Global Plasma Protein Therapeutics market is expected to reach $38.99 billion by 2026 growing at a CAGR of 6.3% during the forecast period.

Development of novel products that offer clinical benefits such as improved efficacy and easy sample plasma extraction techniques are expected to increase penetration of plasma proteins in the market.

Favourable reimbursement policies and improved standard of living have led to increased life expectancy, contributing to rise in geriatric population are driving the market growth. However, aging is considered the greatest risk factor for the development of cardiovascular and neurological diseases.

Based on the Product, the Immunoglobulin (IG) segment is dominating the global plasma protein therapeutics market and is estimated to have a lucrative growth due to the approval of biologics for multiple indications, easy administration process and less treatment cost.

The key vendors mentioned are Abbott, Amgen Inc, Baxter, Bayer AG, Biotest AG, BPL, Chengdu Institute of Biology (CIB), China Biologic Products Holdings, Inc., CSL Behring, Eli Lilly and Company, Grifols, S.A., Hualan Bio, Kamada, Kedrion S.P.A, and LFB Group.

Key Questions Answered in this Report

  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analyzed during the forecast period

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Plasma Protein Therapeutics Market, By Product

5.1 Introduction

5.2 Albumin

5.3 Alpha-1 Proteinase Inhibitors

5.4 C1-Esterase Inhibitors

5.5 Coagulation Factors

5.6 Hyperimmune Globulins

5.7 Immunoglobulin (IG)

5.8 Plasma-Derived Factor VIII

5.9 Plasma-Derived Factor IX

5.10 Polyvalent IVIG/SCIG

5.11 Other Products

6 Global Plasma Protein Therapeutics Market, By Application

6.1 Introduction

6.2 Hemophilia

6.3 Idiopathic Thrombocytopenic Purpura (ITP)

6.4 Primary Immunodeficiency Disorder (PID)

6.5 Secondary Immunodeficiency

6.6 Hereditary Angioedema

6.7 Other Applications

7 Global Plasma Protein Therapeutics Market, By Geography

7.1 North America

7.2 Europe

7.3 Asia Pacific

7.4 South America

7.5 Middle East & Africa

8 Strategic Benchmarking

9 Vendors Landscape

9.1 Abbott

9.2 Amgen Inc

9.3 Baxter

9.4 Bayer AG

9.5 Biotest AG

9.6 BPL

9.7 Chengdu Institute of Biology (CIB)

9.8 China Biologic Products Holdings, Inc.

9.9 CSL Behring

9.10 Eli Lilly and Company

9.11 Grifols, S.A.

9.12 Hualan Bio

9.13 Kamada

9.14 Kedrion S.P.A

9.15 LFB Group

For more information about this report visit https://www.researchandmarkets.com/r/wglszd

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/20/2019 12:40 PM/DISC: 11/20/2019 12:40 PM

Copyright Business Wire 2019.